In GBM, Jacobs and colleagues found that organoid responsiveness to gefitinib for tumors with EGFR alterations, trametinib for NF-1-mutated tumors, everolimus for PI3K-mutated tumors, and EGFRvIII-targeted CAR-T cells could be generally predictive for the response of the parent tumor16. Here, EGFR is linked to glioblastoma.